Stonehouse Jon P's Form 4 filing
Biocryst Pharmaceuticals IncBCRX · filed May 15, 2024
- Accession no.
- 0001127602-24-015365
- Filed
- May 15, 2024
- Trade date
- May 13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $166.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stonehouse Jon PCIK 0001385496 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2024 | Common Stock | PPurchaseAcquired | +30,000 | $5.55F1 | +$166,500 | 1,127,770 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.34 to $5.68. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.